STCube Holds Scientific Advisory Committee at SITC Conference... "Accelerating Immuno-Oncology Drug Development"

[Asia Economy Reporter Hyunseok Yoo] STCube, an immuno-oncology drug development company, announced on the 16th that it has launched a Scientific Advisory Board (SAB) composed of globally renowned experts in the field of immunotherapy to accelerate therapeutic research and development and strengthen clinical research capabilities. The Scientific Advisory Board (SAB) held its official first meeting on the 13th (Korean time) during the Society for Immunotherapy of Cancer (SITC) conference.

STCube's Scientific Advisory Board (SAB) will be responsible for design and academic consultation for the clinical trial of the new immune checkpoint inhibitor drug candidate ‘STT-003,’ scheduled to be conducted in the United States in the second half of next year. Many of the advisory board members will directly participate as researchers in the clinical trial, concurrently conducting patient recruitment, treatment, and outcome analysis while providing academic advice.

The Scientific Advisory Board (SAB) consists of specialists in oncology, clinical trial experts, immuno-oncology experts, biomarker specialists, and biostatistics experts.

Key figures include David Hong, a clinical trial specialist at MD Anderson Cancer Center (MDACC) and the principal investigator of this Phase 1 clinical trial, as well as Dr. Steven Lin, a radiation oncology specialist.

Also participating are Dr. Mario Sznol of Yale Cancer Center, currently serving as the chair of the Society for Immunotherapy of Cancer (SITC), along with Roy Herbst and Patricia LoRusso, authorities in immuno-oncology clinical research, and Dr. Margaret Callahan of Memorial Sloan Kettering Cancer Center (MSKCC). According to the company, all of these individuals are world-leading experts who have achieved significant accomplishments in the field of immuno-oncology clinical research from its early stages.

Additionally, Dr. Aung Naing of MD Anderson Cancer Center (MDACC), an expert in immuno-oncology clinical research and biomarker development, and Dr. Brian Hobbs of the University of Texas, a biostatistics expert, are participating. Dr. Naoko Takebe, senior investigator in new drug development at the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD) at the National Cancer Institute (NCI), will provide consultation on early clinical trial design and evaluation.

An STCube official stated, “World-renowned scholars in the field of immuno-oncology, who are difficult to gather at once, have highly evaluated the clinical success potential of the ‘STT-003 program’ and participated in the Scientific Advisory Board (SAB). We will actively accept in-depth advice and various proposals.” He added, “Through close collaboration with the SAB members, we will finalize the design of the clinical trial targeted for the second half of next year and make our best efforts to obtain the U.S. FDA’s Investigational New Drug (IND) approval and achieve successful clinical trial results.”

This content was produced with the assistance of AI translation services.